Medical device company PAVmed has signed a definitive licensing agreement with academic institutions to develop antibiotic-eluting resorbable ear tubes.

Under the agreement, PAVmed will assume an exclusive worldwide license to develop and market the ear tubes based on aqueous silk technology developed and patented by the collaborating insitutions, Tufts University and two Harvard Medical School teaching hospitals.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The two Harvard Medical School teaching hospitals are Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital.

"According to Harvard Medical School otolaryngology professor Christopher Hartnick, the antibiotic-eluting resorbable ear tube technology will improve pediatric care with complex or recurrent otitis media."

PAVmed chairman Lishan Aklog said: “We are thrilled to partner with these world-renowned institutions to develop and commercialize this revolutionary technology.

"Academic medical centers and individual clinician innovators have often struggled to advance their medical device innovations to commercialisation.

"One of PAVmed’s central goals has been to provide innovators with a rapid, capital-efficient and streamlined pathway to commercialisation, free from traditional structural and capital constraints.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"We anticipate this agreement will serve as a model for future engagements with medical device innovators worldwide.”

According to Harvard Medical School otolaryngology professor Christopher Hartnick, the antibiotic-eluting resorbable ear tube technology will improve pediatric care with complex or recurrent otitis media.

He stated that it has the potential to result in clinical benefits such as eliminating the post-operative ear drop regimen, which is a major challenge for parents, and eliminating the need for a second operation to remove retained tubes.

The ear device will also lead to lesser complications such as ear tubes remaining in the ear canals after getting detached and causing pain or bleeding, which may necessitate a separate procedure to remove the tubes, or obstructing a clear view of the ear drum to identify occult middle ear infection.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact